

# Roman Gulati

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6028812/publications.pdf>

Version: 2024-02-01

123  
papers

6,596  
citations

81900

39  
h-index

66911

78  
g-index

126  
all docs

126  
docs citations

126  
times ranked

9421  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multicancer Early Detection: Learning From the Past to Meet the Future. Journal of the National Cancer Institute, 2022, 114, 349-352.	6.3	22
2	A Quantitative Framework to Study Potential Benefits and Harms of Multi-Cancer Early Detection Testing. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 38-44.	2.5	8
3	A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. European Urology, 2022, 81, 576-585.	1.9	21
4	Inherited TP53 Variants and Risk of Prostate Cancer. European Urology, 2022, 81, 243-250.	1.9	40
5	Stage Shift as an Endpoint in Cancer Screening Trials: Implications for Evaluating Multicancer Early Detection Tests. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1298-1304.	2.5	14
6	Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men. , 2022, 1, .		23
7	Evaluation of Prostate Cancer Screening Strategies in a Low-Resource, High-risk Population in the Bahamas. JAMA Health Forum, 2022, 3, e221116.	2.2	3
8	Impact of cancer screening on metastasis: A prostate cancer case study. Journal of Medical Screening, 2021, 28, 096914132198973.	2.3	0
9	Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. Nature Communications, 2021, 12, 1426.	12.8	176
10	Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer. Prostate, 2021, 81, 418-426.	2.3	8
11	Clarifying the Trade-Offs of Risk-Stratified Screening for Prostate Cancer: A Cost-Effectiveness Study. American Journal of Epidemiology, 2021, 190, 2064-2074.	3.4	9
12	The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis. Journal of the National Cancer Institute, 2021, 113, 1336-1342.	6.3	22
13	Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States. Value in Health, 2021, 24, 1111-1117.	0.3	9
14	When to Discuss Prostate Cancer Screening With Average-Risk Men. American Journal of Preventive Medicine, 2021, 61, 294-298.	3.0	1
15	Divining Harm-Benefit Tradeoffs of Magnetic Resonance Imaging-targeted Biopsy. European Urology, 2021, 80, 573-574.	1.9	1
16	Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline <i>ATM</i> versus <i>BRCA2</i> mutations. Prostate, 2021, 81, 1382-1389.	2.3	10
17	Prostate-Specific Antigen Screening and Recent Increases in Advanced Prostate Cancer. JNCI Cancer Spectrum, 2021, 5, pkaa098.	2.9	9
18	Overdiagnosis and Lives Saved by Reflex Testing Men With Intermediate Prostate-Specific Antigen Levels. Journal of the National Cancer Institute, 2020, 112, 384-390.	6.3	10

#	ARTICLE	IF	CITATIONS
19	Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts. <i>European Urology</i> , 2020, 77, 144-155.	1.9	46
20	Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1667-1677.	7.0	30
21	Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer. <i>PLoS ONE</i> , 2020, 15, e0239686.	2.5	6
22	Reconsidering the Trade-offs of Prostate Cancer Screening. <i>New England Journal of Medicine</i> , 2020, 382, 2465-2468.	27.0	53
23	Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress. <i>Cell Reports</i> , 2020, 31, 107669.	6.4	167
24	Lifetime Benefits and Harms of Prostate-Specific Antigen-Based Risk-Stratified Screening for Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1013-1020.	6.3	23
25	CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. <i>JCO Precision Oncology</i> , 2020, 4, 382-392.	3.0	51
26	Reply by Authors. <i>Journal of Urology</i> , 2020, 203, 842-842.	0.4	0
27	Randomized trial evaluating the role of weight loss in overweight and obese men with early stage prostate Cancer on active surveillance: Rationale and design of the Prostate Cancer Active Lifestyle Study (PALS). <i>Contemporary Clinical Trials</i> , 2019, 81, 34-39.	1.8	15
28	Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. <i>Prostate</i> , 2019, 79, 701-708.	2.3	18
29	A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data. <i>PLoS ONE</i> , 2019, 14, e0211918.	2.5	10
30	Cancer Outcomes in DCIS Patients Without Locoregional Treatment. <i>Journal of the National Cancer Institute</i> , 2019, 111, 952-960.	6.3	76
31	Identification of the Fraction of Indolent Tumors and Associated Overdiagnosis in Breast Cancer Screening Trials. <i>American Journal of Epidemiology</i> , 2019, 188, 197-205.	3.4	12
32	Estimating the frequency of indolent breast cancer in screening trials. <i>Statistical Methods in Medical Research</i> , 2019, 28, 1261-1271.	1.5	6
33	Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication. <i>Journal of Urology</i> , 2019, 202, 936-943.	0.4	14
34	Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative trial in high risk localized prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5081-5081.	1.6	0
35	Abstract 379: Supraphysiological testosterone inhibits tumor growth and is associated with inhibition of ARV7 signaling and DNA damage response in preclinical models of enzalutamide-resistant prostate cancer. , 2019, , .		0
36	Reply by Authors. <i>Journal of Urology</i> , 2019, 202, 943-943.	0.4	0

#	ARTICLE	IF	CITATIONS
37	Racial disparities in prostate cancer survival in a screened population: Reality versus artifact. <i>Cancer</i> , 2018, 124, 1752-1759.	4.1	12
38	Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e161-e167.	1.9	3
39	The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials. <i>Cancer</i> , 2018, 124, 1197-1206.	4.1	56
40	Estimating and comparing cancer progression risks under varying surveillance protocols. <i>Annals of Applied Statistics</i> , 2018, 12, 1773-1795.	1.1	8
41	When Clinical Trials Disagree. <i>Journal of Urology</i> , 2018, 200, 506-507.	0.4	0
42	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. <i>Annals of Internal Medicine</i> , 2018, 168, 608.	3.9	16
43	A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. <i>PLoS ONE</i> , 2018, 13, e0198389.	2.5	86
44	Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival. <i>Prostate</i> , 2018, 78, 1077-1083.	2.3	0
45	Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. <i>Annals of Internal Medicine</i> , 2018, 168, 1.	3.9	33
46	Proportion of biochemically-recurrent prostate cancer patients with durable undetectable PSA after short-course androgen deprivation therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 207-207.	1.6	1
47	Association of undetectable PSA with time to metastasis and survival after short-course androgen deprivation therapy for biochemically-recurrent prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e17073-e17073.	1.6	0
48	A Matched Cohort Analysis of Prostate Cancer Screening in Younger Men in Sweden. <i>European Urology</i> , 2017, 71, 53-54.	1.9	1
49	Is prostate cancer different in black men? Answers from 3 natural history models. <i>Cancer</i> , 2017, 123, 2312-2319.	4.1	100
50	Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting the risk of progression. <i>Histopathology</i> , 2017, 71, 406-414.	2.9	19
51	Insights from the PLCO trial about prostate cancer screening. <i>Cancer</i> , 2017, 123, 546-548.	4.1	2
52	A Framework for Treatment Decision Making at Prostate Cancer Recurrence. <i>Medical Decision Making</i> , 2017, 37, 905-913.	2.4	6
53	Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4592-4601.	7.0	31
54	Characterization of an Abiraterone Ultrasensitive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts. <i>Clinical Cancer Research</i> , 2017, 23, 2301-2312.	7.0	20

#	ARTICLE	IF	CITATIONS
55	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. <i>Annals of Internal Medicine</i> , 2017, 167, 449.	3.9	160
56	Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 222-227.	2.5	33
57	A Novel System for Estimating Residual Disease and Pathologic Response to Neoadjuvant Treatment of Prostate Cancer. <i>Prostate</i> , 2016, 76, 1285-1292.	2.3	11
58	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 443-453.	27.0	1,205
59	Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies. <i>American Journal of Epidemiology</i> , 2016, 184, 140-147.	3.4	26
60	MPO2-07 NOVEL URINE MARKERS FOR DIAGNOSING AND MONITORING NON-INDOLENT PROSTATE CANCER. <i>Journal of Urology</i> , 2016, 195, .	0.4	0
61	Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer. <i>Medical Oncology</i> , 2016, 33, 77.	2.5	11
62	Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. <i>JAMA Oncology</i> , 2016, 2, 890.	7.1	65
63	Recent Trends in PSA Testing and Prostate Cancer Incidence. <i>JAMA Oncology</i> , 2016, 2, 955.	7.1	28
64	Active Surveillance for Ductal Carcinoma in Situ: Shining Light Into the Modeling Abyss. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv378.	6.3	1
65	Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. <i>Nature Medicine</i> , 2016, 22, 369-378.	30.7	572
66	Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. <i>Oncotarget</i> , 2016, 7, 40690-40703.	1.8	12
67	Androgen content and BET bromodomain proteins influence enzalutamide agonism of mutant F876L androgen receptor.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16538-e16538.	1.6	0
68	Recognizing the Limitations of Cancer Overdiagnosis Studies: A First Step Towards Overcoming Them. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv345-djv345.	6.3	30
69	Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 122-127.	3.9	78
70	Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 677-682.	2.5	17
71	Relationships Between Times to Testosterone and Prostate-Specific Antigen Rises During the First Off-Treatment Interval of Intermittent Androgen Deprivation are Prognostic for Castration Resistance in Men With Nonmetastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 10-16.	1.9	16
72	Measures of survival benefit in cancer drug development and their limitations. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 122-127.	1.6	4

#	ARTICLE	IF	CITATIONS
73	Novel urine markers for diagnosing and monitoring non-indolent prostate cancer.. Journal of Clinical Oncology, 2015, 33, e16113-e16113.	1.6	1
74	Improving the value of PSA prostate cancer screening with "smarter" strategies and increased use of active surveillance.. Journal of Clinical Oncology, 2015, 33, 6616-6616.	1.6	0
75	Abstract 4313: Abiraterone acetate (AA) treatment of prostate cancer patient-derived xenografts (PDX) demonstrates heterogeneity of responses and identifies potential biomarkers of adaptive resistance. , 2015, , .		0
76	Chemotherapy-Induced Monoamine Oxidase Expression in Prostate Carcinoma Functions as a Cytoprotective Resistance Enzyme and Associates with Clinical Outcomes. PLoS ONE, 2014, 9, e104271.	2.5	30
77	A Reality Check for Overdiagnosis Estimates Associated With Breast Cancer Screening. Journal of the National Cancer Institute, 2014, 106, dju315-dju315.	6.3	40
78	Individualized Estimates of Overdiagnosis in Screen-Detected Prostate Cancer. Journal of the National Cancer Institute, 2014, 106, djt367-djt367.	6.3	47
79	Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. International Journal of Cancer, 2014, 135, 939-947.	5.1	39
80	Overdetection of Recurrence after Radical Prostatectomy: Estimates Based on Patient and Tumor Characteristics. Clinical Cancer Research, 2014, 20, 5302-5310.	7.0	19
81	RE: A Model Too Far. Journal of the National Cancer Institute, 2014, 106, dju058-dju058.	6.3	1
82	Expected population impacts of discontinued prostate-specific antigen screening. Cancer, 2014, 120, 3519-3526.	4.1	90
83	Oversimplifying Overdiagnosis. Journal of General Internal Medicine, 2014, 29, 1218-1220.	2.6	13
84	Targeted Androgen Pathway Suppression in Localized Prostate Cancer: A Pilot Study. Journal of Clinical Oncology, 2014, 32, 229-237.	1.6	70
85	Personalizing Age of Cancer Screening Cessation Based on Comorbid Conditions: Model Estimates of Harms and Benefits. Annals of Internal Medicine, 2014, 161, 104.	3.9	123
86	The effect of prior abiraterone (Abi) use on the activity of enzalutamide (Enza) in men with mCRPC.. Journal of Clinical Oncology, 2014, 32, 18-18.	1.6	28
87	Prostate Cancer Characteristics Associated with Response to Pre-Receptor Targeting of the Androgen Axis. PLoS ONE, 2014, 9, e111545.	2.5	6
88	Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways. Oncotarget, 2014, 5, 9939-9951.	1.8	92
89	Abstract 4011: Single cell transcriptomic analysis identified a potential dormant signature in prostate cancer disseminated tumor cells. , 2014, , .		0
90	Single cell transcriptomic analysis of prostate cancer cells. BMC Molecular Biology, 2013, 14, 6.	3.0	31

#	ARTICLE	IF	CITATIONS
91	Effects of Screening on Radical Prostatectomy Efficacy: The Prostate Cancer Intervention Versus Observation Trial. <i>Journal of the National Cancer Institute</i> , 2013, 105, 546-550.	6.3	26
92	Deriving benefit of early detection from biomarker-based prognostic models. <i>Biostatistics</i> , 2013, 14, 15-27.	1.5	4
93	Should Modest Elevations in Prostate-Specific Antigen, International Prostate Symptom Score, or Their Rates of Increase Over Time be Used as Surrogate Measures of Incident Benign Prostatic Hyperplasia?. <i>American Journal of Epidemiology</i> , 2013, 178, 741-751.	3.4	1
94	Response. <i>Medical Care</i> , 2013, 51, 304-306.	2.4	8
95	Limitations of Basing Screening Policies on Screening Trials. <i>Medical Care</i> , 2013, 51, 295-300.	2.4	63
96	Influence of Study Features and Methods on Overdiagnosis Estimates in Breast and Prostate Cancer Screening. <i>Annals of Internal Medicine</i> , 2013, 158, 831.	3.9	117
97	Comparative Effectiveness of Alternative Prostate-Specific Antigen-Based Prostate Cancer Screening Strategies. <i>Annals of Internal Medicine</i> , 2013, 158, 145.	3.9	144
98	Alternative Prostate Cancer Screening Strategies. <i>Annals of Internal Medicine</i> , 2013, 158, 778.	3.9	1
99	A pilot study of high-dose exisulind in men with biochemical relapse (BCR) of prostate cancer after definitive local therapy treated with intermittent androgen deprivation (IAD).. <i>Journal of Clinical Oncology</i> , 2013, 31, 209-209.	1.6	1
100	Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling. <i>PLoS ONE</i> , 2013, 8, e78881.	2.5	60
101	Long-Term Dynamics of Bone Mineral Density During Intermittent Androgen Deprivation for Men With Nonmetastatic, Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 1864-1870.	1.6	40
102	Prostate Cancer Mortality following Active Surveillance versus Immediate Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2012, 18, 5471-5478.	7.0	52
103	The prostate cancer conundrum revisited. <i>Cancer</i> , 2012, 118, 5955-5963.	4.1	125
104	The impact of PLCO control arm contamination on perceived PSA screening efficacy. <i>Cancer Causes and Control</i> , 2012, 23, 827-835.	1.8	61
105	Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma. <i>BJU International</i> , 2012, 109, 706-712.	2.5	36
106	Relationship of time to testosterone (T) and PSA rises during the first "off treatment" interval (1OFF) of intermittent androgen deprivation (IAD) with time to castration resistance (CRPC) and prostate cancer mortality (PCM) in men with biochemical relapse (BR).. <i>Journal of Clinical Oncology</i> , 2012, 30, 99-99.	1.6	0
107	Abstract 5237: Interrogating cell heterogeneity and dormancy in prostate cancer disseminated tumor cells. , 2012, , .		0
108	1621 SINGLE CELL TRANSCRIPTOMIC PROFILING OF PROSTATE CANCER CELLS. <i>Journal of Urology</i> , 2011, 185, .	0.4	0

#	ARTICLE	IF	CITATIONS
109	Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 1412-1417.	5.0	43
110	Associations of obesity with triglycerides and C-reactive protein are attenuated in adults with high red blood cell eicosapentaenoic and docosahexaenoic acids. <i>European Journal of Clinical Nutrition</i> , 2011, 65, 808-817.	2.9	59
111	What If I Don't Treat My PSA-Detected Prostate Cancer? Answers from Three Natural History Models. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 740-750.	2.5	43
112	Abstract 5242: Obtaining a transcriptomic profile of a single prostate cancer cell. , 2011, , .		0
113	Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells. <i>Anti-Cancer Drugs</i> , 2010, 21, 423-432.	1.4	71
114	The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells. <i>Prostate</i> , 2010, 70, 412-424.	2.3	42
115	Associations of very high intakes of eicosapentaenoic and docosahexaenoic acids with biomarkers of chronic disease risk among Yup'ik Eskimos. <i>American Journal of Clinical Nutrition</i> , 2010, 91, 777-785.	4.7	45
116	Duration of First Off-Treatment Interval Is Prognostic for Time to Castration Resistance and Death in Men With Biochemical Relapse of Prostate Cancer Treated on a Prospective Trial of Intermittent Androgen Deprivation. <i>Journal of Clinical Oncology</i> , 2010, 28, 2668-2673.	1.6	61
117	Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. <i>Biostatistics</i> , 2010, 11, 707-719.	1.5	45
118	Effect of Population Trends in Body Mass Index on Prostate Cancer Incidence and Mortality in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 808-815.	2.5	25
119	Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context. <i>Journal of the National Cancer Institute</i> , 2009, 101, 374-383.	6.3	668
120	Overview of US Prostate Cancer Trends in the Era of PSA Screening. , 2009, , 3-14.		3
121	Estimating Lead Time and Overdiagnosis Associated with PSA Screening from Prostate Cancer Incidence Trends. <i>Biometrics</i> , 2008, 64, 10-19.	1.4	101
122	Quantifying the role of PSA screening in the US prostate cancer mortality decline. <i>Cancer Causes and Control</i> , 2008, 19, 175-181.	1.8	345
123	Impact of PSA Screening on the Incidence of Advanced Stage Prostate Cancer in the United States: A Surveillance Modeling Approach. <i>Medical Decision Making</i> , 2008, 28, 323-331.	2.4	88